Since the first pandemic wave in early 2020, the severe acute respiratory disease caused by Coronavirus-19 (COVID-19) has been the subject of much scientific research with the aim of specifically evaluating its potential negative impact in the neurological field, and in particular in the context of chronic neurodegenerative diseases such as Parkinson’s disease and other parkinsonian diseases (atypical and unspecified parkinsonisms).

Parkinson’s disease patients no more likely to contract Covid-19

It is believed that the risk of contracting COVID-19 in people with Parkinson’s disease and other parkinsonism does not differ from the general population, ”commented Alfredo Berardelli, president of the Italian Society of Neurology.

Recent studies and meta-analytical evidence indicate that the risk of hospitalization (around 50%) and death (around 10%) of these patients once they contract COVID-19, depends mainly on their age, which is generally advanced, and possible comorbidities ”.

On the other hand, the indirect consequences of COVID-19 have been significant, such as the difficulties, and in some cases the unavailability, of accessing medical care and physiotherapy during periods of reduced mobility, which has without any doubt represented an additional burden in the clinical management of patients with Parkinson’s disease and parkinsonism, even those who were not infected with COVID-19.

“It is important to stress – concludes Berardelli – that the scientific evidence available today does not contraindicate the use of COVID-19 vaccines in the population of people with Parkinson’s disease and other parkinsonism.

For this reason, vaccination of all patients is recommended.

National Parkinson’s Day is organized by the Limpe-Dismov Academy (the main scientific association for Parkinson’s disease in Italy), member of the Italian Society of Neurology, in collaboration with the Limpe Foundation for Parkinson’s disease Onlus.

Parkinson’s disease is a neurodegenerative disease that currently affects 5 million people worldwide, including over 300,000 60 in Italy alone, and occurs on average around XNUMX years.

It is estimated that this number is destined to increase in our country and that over the next 15 years there will be 6,000 new cases every year, half of which will occur of working age.

Diagnosis of the disease is primarily clinical and symptom-based.

Instrumental exams such as brain MRI and hematochemical tests can help rule out diseases that have similar symptoms.

Confirmation of the diagnosis can come from specific tests such as Spect and Pet.

Read also:

Dementia, COVID-19-linked hypertension in Parkinson’s disease

Risk of Parkinson’s disease after COVID-19: Australian research A

Parkinson’s disease: changes in brain structures associated with worsening of the disease identified


Dire Agency

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.